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Infections after CD34-selected or
unmanipulated autologous hematopoietic
stem cell transplantation
High-dose chemotherapy followed by autologous
stem cell transplantation can improve survival for
several categories of cancer patients (1–3). Periph-
eral blood stem cells (PBSC) have replaced bone
marrow (BM) in this indication because they allow
a more rapid trilineage hematopoietic recovery,
leading to a reduction in the incidence of febrile
neutropenia, duration of hospital stay and utiliza-
tion of blood products (4). Despite this, relapse
and tumor contamination of the graft has been
advocated as a major cause of failure of PBSC
transplant. As the CD34 antigen is a surface
marker expressed in early hematopoietic progen-
itors but is not present in mature hematopoietic
cells or most tumor cells, CD34 selection has been
used to reduce the amount of contaminant tumor
cells in the stem cell product (5, 6). Although the
number of contaminating tumor cells can be
reduced by two to four logs, it is not yet known
whether CD34 selection would signiﬁcantly impact
on the incidence of relapse (5, 7). However, there
are suggestions that immune reconstitution may be
delayed with CD34 selection because of the
removal of T cells, natural killer cells and mono-
cytes (8–11). The result could be an increased
incidence of infectious complications. Some small
series of patients have reported a higher incidence
of infections (12–14), in particular of viral infec-
tions (15–17), but others have not (8). We there-
fore compared in a retrospective case–control
matched study the incidence of infection in 25
CD34-selected PBSC transplant recipients and in
75 patients receiving unmanipulated PBSC in our
institution.
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Abstract: Immune reconstitution may be delayed after CD34-selected
compared with unmanipulated autologous peripheral blood stem cell
transplantation (PBSCT), resulting in a theoretically increased risk of
infections. In a case–control matched study we compared the incidence
of infection in 25 recipients of CD34-selected PBSC (CD34 group) and
75 recipients of unmanipulated PBSC (PBSC group) transplants. The
population included 52 males and 48 females suﬀering from non-
Hodgkin’s lymphoma (n ¼ 32), Hodgkin’s disease (n ¼ 8), multiple
myeloma (n ¼ 40) or breast cancer (n ¼ 20). Neutrophil engraftment
was comparable in the two groups. The actuarial incidence of infection
was similar in the two groups (56% vs. 49% at day 30, and 70% vs. 64%
at 1 yr respectively). The proportion of patients with 1, 2 or 3 infections,
the number of infectious event per patient (1.32 vs. 1.04; NS), the
number of infections before day 15 or 30, between days 31 and 100 or
after day 100, the risk of varicella-zoster virus or cytomegalovirus
infection or disease, or the use of antibiotic or antifungal therapy, were
not increased in the CD34 compared with the PBSC group. The main
agents responsible for infection were bacteria, particularly gram-positive
cocci, in both groups. Bacteremia accounted for 33% of all infectious
events in the CD34 group vs. 16% in the PBSC group (P < 0.05).
Fungal infections were rare. In conclusion, our results do not support
the notion that CD34-selection of the graft is associated with an in-
creased rate of infection after autologous PBSC transplantation. The
role of extended infection prophylaxis should be evaluated.
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Patients characteristics are displayed in Table 1.
The study population included all patients receiving
a CD34-selected PBSC autograft in our center
(CD34 group, n ¼ 25), as part of pilot studies. We
then proceeded to select 75 controls in our database
of 327 patients receiving an unmanipulated PBSC
transplant during the same period of time. After
exclusion of patients receiving PBSC + BM (n ¼
30), patients with a diagnosis other than multiple
myeloma (MM), non-Hodgkin’s lymphoma
(NHL), Hodgkin’s disease (HD) or breast cancer
(BC) (n ¼ 58) and patients with a follow-up <30 d
(n ¼ 12), 223 patients were available for matching.
The CD34 group was then matched 1 : 3 with the
unmanipulated patients (PBSC group) on the basis
of diagnosis, disease status at time of transplant
and transplantation number (ﬁrst or second trans-
plant). This was achieved for NHL, HD and BC
but not for MM because CD34 selection in this
indication was only performed for second trans-
plantation after relapse. Therefore, a higher pro-
portion of MM patients in the CD34 group were in
relapse and fewer in ﬁrst partial remission. The
median follow-up was 771 d. All patients gave
written informed consent to the collection and
analysis of their clinical data and this was approved
by the Ethics Committee of the University of Lie`ge.
PBSC collection and CD34 selection
Peripheral blood stem cell were mobilized in all
patients by a combination of disease-oriented
chemotherapy and granulocyte colony-stimulating
factor (G-CSF) 5 lg/kg/d. PBSC were harvested by
leukapheresis as previously described (6, 18). CD34
selection was carried out with an avidin immuno-
aﬃnity column device (Ceprate SC system; Cell-
Pro, Bothell, WA, USA) as previously described
(6). Unmanipulated as well as CD34-selected cells
were frozen in 7.5% DMSO to be thawed and
infused through a central catheter, as previously
described (6).
Clinical management
Until engraftment, patients were kept in laminar air
ﬂow rooms and received chlorhexidine mouthwa-
shes, aerosolized amphotericin B, oral ciproﬂoxacin
(500 mg b.i.d.) as well as G-CSF (5 lg/kg/d).
Patients also received acyclovir (250 mg/m2 b.i.d.
intravenously and then orally as soon as feasible
until day 100), oral antifungal prophylaxis with
either 400 mg itraconazole (n ¼ 75) or 400 mg
ﬂuconazole if itraconazole was not tolerated (n ¼
25) until day 100 and aerosolized pentamidine until
day 120. All patients were managed with a totally
implanted Porth-A-Cath catheter (Bard, Coving-
ton, GA, USA) that remained in place at least until
1 yr post-transplant.
In case of fever, above 38.3C once or above
38C on three consecutive measurements, empirical
antibiotic therapy was started with a combination
of ceftazidime + vancomycin (until 2000) or
Table 1. Patients characteristics
CD34 group PBSC group P-value
Age (yr) 51 € 11 52 € 11 NS
Sex
Female 11 (44) 37 (49) NS
Male 14 (56) 38 (51)
Diagnosis
Non-Hodgkin's lymphoma 8 (32) 24 (32) NS
Hodgkin's disease 2 (8) 6 (8)
Multiple myeloma 10 (40) 30 (40)
Breast cancer 5 (20) 15 (20)
Lines of treatment 2.6 € 1.1 2.4 € 1.1 NS
Status at transplant
CR 1 and 2 6 (24) 18 (24) NS
Other first line 5 (20) 25 (33)
Relapse 14 (56) 32 (43)
Conditioning regimen
TBI 13 (52) 20 (27) 0.020
12 GY + CY 120 4 (16) 11 (15)
12 GY + Mel 140 9 (36) 9 (12)
Chemotherapy 12 (48) 55 (73)
Mel 200 1 (4) 19 (25)
BEAM 6 (24) 16 (21)
CTCb 5 (20) 15 (20)
Other 0 (0) 5 (7)
Transplant number
First 15 (60) 48 (64) NS
Second 10 (40) 27 (36)
Cytomegalovirus status
Positive 15 (60) 44 (59) NS
Negative 10 (40) 31 (41)
Herpes simplex virus status
Positive 24 (96) 62 (83) NS
Negative 1 (4) 12 (17)
Varicella-zoster virus status
Positive 24 (96) 61 (81) NS
Negative 1 (4) 9 (19)
Mucositis
Grade 0 13 (52) 26 (35) NS
Grade 1 8 (32) 31 (41)
Grade 2 4 (16) 18 (24)
Gastrointestinal toxicity
Grade 0 12 (48) 37 (49) NS
Grade 1 13 (52) 37 (49)
Grade 2 0 (0) 1 (2)
CD34+ cells infused 10.2 € 11.3 13.2 € 13.3 NS
Median days of G-CSF 12 10 NS
Median days to 500 PMN 10 9 NS
Monocytes on day 30 593 € 76 670 € 52 NS
Lymphocytes on day 30 866 € 159 1061 € 88 NS
Percentage values are given in parentheses. CR, complete remission; Gy, Grays; Cy,
cyclophosphamide; Mel, melphalan; BEAM, BCNU + VP16 + ARA-C + melphalan;
CTC6, cyclophosphamide + thiotepa + carboplatin.
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cefepime + amikacin (after 2000) (19). Patients
were weekly screened for cytomegalovirus (CMV)
by culture and antigenemia in blood and urine
before 1996 and by PCR in blood since 1996. Hence
55% in the PBSC group vs. 25% in the CD34
group were screened by PCR. Preemptive therapy
with ganciclovir (10 mg/kg i.v. thrice weekly) was
initiated after a positive antigenemia or culture
(before 1996) or a positive PCR (since 1996) and
discontinued after two consecutive negative results.
Other viruses, in particular respiratory viruses, are
not routinely screened in our institution.
Definitions
Bacteria were classiﬁed into ﬁve categories taking
into account both their relative frequency and their
biological characteristics. These categories were: (i)
streptococci (including pneumococci and entero-
cocci), (ii) coagulase-negative staphylococci, (iii)
other gram-positive bacteria (including Staphylo-
coccus aureus), (iv) anerobic bacteria (bacteria
requiring absence of oxygen for growth, including
both strict anaerobes and aerotolerant bacteria), (v)
gram-negative bacteria (including pseudomonas)
(19). We used the deﬁnitions of the Infectious
Diseases Working Party of the EBMT for diagnos-
tic of bacteremia, fungemia, herpes simplex virus
(HSV) or varicella-zoster virus (VZV) infections,
CMV infection or disease (20). As quantitative
assessment of bacteria load was not available,
bacteremia could not be separated between those
linked and those not linked to the catheter. Invasive
fungal infections were deﬁned according to the
EORTC criteria (21). Fever of unknown origin
(FUO) was deﬁned as fever alone without any
clinical sign or bacteriological documentation.
Toxicities were graded using the Bearman toxicity
scale that was speciﬁcally developed for the setting
of stem cell transplantation (22).
Statistical analysis
Patients were censored at the time of disease
progression to avoid the confounding eﬀect of
disease and chemotherapy-induced neutropenia.
Chi-square tests, unpaired t-tests or one-way anova
were used to compare diﬀerences between groups,
as appropriate. The number of events in the two
groups was compared by the Z-test. Times to
hematopoietic recovery or infectious events were
studied by life table analyses and Wilcoxon rank
tests were used for comparison between groups.
Statistical analyses were done using Microsoft
Excel (Microsoft Corp., Redmond, WA, USA)
and GraphPad Prism (GraphPad Software, San
Diego, CA, USA) software.
Results
The median number of CD34 cells infused (purity
67 ± 19%), the median duration of G-CSF ther-
apy and neutrophil and monocyte engraftment
were similar in the two groups (Table 1). Platelet
and red blood cell engraftment and transfusion
independence were also quite comparable (data not
shown). Lymphocyte counts were lower in the
CD34 group on day 14 (138 ± 150 vs. 535 ± 607,
P ¼ 0.0027) but quite similar thereafter throughout
to day 365. CD3, CD4 and CD8 cell counts were
available in a minority of patients. Whereas they
were all lower through to day 42 (P < 0.05), the
diﬀerences were no longer present at later time
points. CD56 counts were similar throughout the
post-transplant course. Serum IgG were higher in
the CD34 group on day 100 (17.19 ± 4.47 g/L vs.
12.28 ± 3.56 g/L, P ¼ 0.0002) but similar on days
180 and 365. Serum IgM were lower in the CD34
group on day 180 (0.35 ± 0.14 g/L vs.
0.63 ± 0.64 g/L, P ¼ 0.0107), but there were no
other diﬀerences for IgM and IgA. Mucosal or
gastrointestinal toxicities were similar. Only two
patients in the PBSC group had hemorrhagic
cystitis (negative viral cultures). Progression-free
survival was not signiﬁcantly diﬀerent in the CD34
group compared with the PBSC group and similar
numbers of patients were censored for disease
progression at day 100 and at 1 yr. The main cause
of death was the initial disease in both groups
(100% of the deaths in the CD34 group and 86% in
the PBSC group). Infection was the main cause or a
contributing cause of death in, respectively, 0% and
20% of patients in the CD34 group compared with
1% (NS) and 10% (NS), respectively, in the PBSC
group.
The proportion of patients with at least one
(68% vs. 68%), two (24% vs. 17%) or three (4%
vs. 4%) infections after transplantation was not
diﬀerent in the CD34 and PBSC groups and this
holds true for infections occurring before day 100.
The actuarial incidence of infection at day 30, day
100 and 1 yr was similar in the CD34 and PBSC
groups (Fig. 1A). As each patient could develop
more than one infectious episode, we also calcula-
ted the number of events in each group at diﬀerent
time intervals after transplantation (Table 2). There
was no diﬀerence between the two groups
(1.32 event/patient vs. 1.04 event/patient), even
when FUO were excluded (1.04 event/patient vs.
0.81 event/patient). Indeed, 45% (15/33) and 53%
(41/78) of all infections occurred during the ﬁrst
15 d (i.e. during neutropenia) in the CD34 and
PBSC groups respectively. Bacteria were involved
in most cases (21 vs. 56), while similarly low
numbers of fungal (3 vs. 6), viral (7 vs. 13) and
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parasitic (0 vs. 0) infections were observed in the
CD34 and PBSC groups respectively. During initial
hospitalization, there was no diﬀerence in the
median number of days with fever (1 d vs. 1 d),
with amphotericin B (0 d vs. 0 d) or with antibiot-
ics (8 d vs. 5 d) in the CD34 group compared with
the PBSC group.
Overall the CD34 and PBSC groups had similar
risks of viral infections despite greater usage of TBI
in the CD34 group (Table 2). Five vs. eight cases of
dermatomal and one vs. three cases of disseminated
VZV infection occurred in the CD34 and PBSC
groups respectively. The actuarial proportion of
patients with VZV infection at 1 yr or 5 yr was
similar in the two groups (Fig. 1B). CMV reacti-
vation occurred in 2/25 (8%) in the CD34 group vs.
5/75 (6%) in the PBSC group, but CMV disease
was only observed in the PBSC group (one case of
gastroenteritis before day 30 and one case of
myelosuppression before day 100). CMV infection
or disease were never encountered after day 100.
Bacteremia occurred in 8/25 patients (32%) in
the CD34 group and in 15/75 patients (20%) in the
PBSC group (P ¼ 0.2169), representing a total of
11 vs. 15 episodes (P < 0.10). The actuarial risk of
bacteremia at day 30 or 1 yr was similar in the
CD34 and PBSC groups respectively (Fig. 1C)
(P ¼ 0.2042). The vast majority of bacteremia took
place during neutropenia in both groups, with only
six events occurring after day 15. Bacteremia
accounted for 33% of all infectious events in the
CD34 group vs. 16% in the PBSC group
(P < 0.05). Among bacteremia, 38% were due to
coagulase-negative staphylococci, 19% to strepto-
cocci and 19% to gram-negative bacteria, with
similar proportions in the two groups. There was
only one candidemia in the CD34 group.
The number of infectious events other than
bacteremia or viral infections was quite comparable
in the two groups (0.64 episode/patient vs. 0.64 epi-
sode/patient). Pneumonias accounted for about
25% of these infections, mostly of bacterial origin
and very few of fungal origin (one vs. two,
respectively). The gastrointestinal tract was the













































































Fig. 1. Actuarial incidence of any infection (A), zoster
infection (B) and bacteremia (C) in the CD34 group com-
pared with the PBSC group.
Table 2. Number of infectious complications (n per patient) in the two groups according to time after transplantation. Infections are classified by etiologic agent
Days 0–30 Days 31–100 Days >100 Total
CD34 group PBSC group P-value CD34 group PBSC group P-value CD34 group PBSC group P-value CD34 group PBSC group P-value
All infections 21 (0.84) 48 (0.64) NS 0 (0.00) 7 (0.09) <0.01 12 (0.48) 23 (0.31) NS 33 (1.32) 78 (1.04) NS
Viral 1 (0.04) 1 (0.01) NS 0 (0.00) 1 (0.01) NS 6 (0.24) 11 (0.15) NS 7 (0.28) 13 (0.17) NS
Fungal 3 (0.12) 5 (0.07) NS 0 (0.00) 0 (0.00) NS 0 (0.00) 1 (0.01) NS 3 (0.12) 6 (0.08) NS
Bacterial 17 (0.68) 40 (0.53) NS 0 (0.00) 6 (0.08) <0.05 4 (0.16) 10 (0.13) NS 21 (0.84) 56 (0.75) NS
Parasitic 0 (0.00) 0 (0.00) NS 0 (0.00) 0 (0.00) NS 0 (0.00) 0 (0.00) NS 0 (0.00) 0 (0.00) NS
Unknown 0 (0.00) 2 (0.03) NS 0 (0.00) 0 (0.00) NS 2 (0.08) 1 (0.01) NS 2 (0.08) 3 (0.04) NS
P-values are given for the calculated incidence per patient. Infections occurring after disease progression are excluded.
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most common site of infection in the PBSC group
(11 cases) but was not encountered in the CD34
group (P < 0.001).
Discussion
We conducted a retrospective matched case–control
study of infections in patients treated by high-dose
chemotherapy and autologous PBSC transplanta-
tion with or without CD34 cell selection. The CD34
group was matched 1 : 3 with the PBSC group on
the basis of diagnosis, disease status and transplan-
tation number. This was not achieved for MM
because CD34 selection in this indication was only
carried out for second transplantation after relapse.
Hence, patients in the CD34 group had somewhat
more advanced disease and received more often
TBI, but otherwise the two groups were very well
balanced (Table 1). This greater use of TBI could
theoretically increase the risk of infection.
Overall, we did not ﬁnd any diﬀerence in the
proportion of patients with any infection between
recipients of CD34-selected or unmanipulated
PBSC grafts. Contrary to some other studies (12–
14), but in agreement with Peggs et al. (8), we did
not ﬁnd an increased incidence of bacterial infec-
tions in recipients of CD34-selected autografts.
This could theoretically be due to an increase of
infections in our PBSC group. However, this did
not appear to be the case in comparison with
previous studies in the literature (3, 6, 23–27). The
mechanisms of this increased rate of bacterial
infection in other studies with CD34 selection
may relate to diﬀerence in neutrophil engraftment
(14) (not encountered in our study), whereas others
did not report neutrophil recovery (12, 13). In
addition, there have been suggestions that TBI (28)
or a diagnosis of myeloma rather than BC (29) were
signiﬁcant risk factors after CD34-selected PBSC
transplantation. However, we did not observe such
a trend for higher rates of infections in patients
receiving TBI and the respective numbers of myel-
oma or BC patients were perfectly matched. There
was no delay in neutrophil engraftment in our
CD34 group. Whereas delayed hematopoietic
recovery has sometimes been described in the
literature (5, 14, 30), it has not been observed in
randomized studies (7) and we have shown previ-
ously that neutrophil counts remained quite similar
in CD34-selected and unselected patients over
periods of months post-transplant (6). Finally,
our policy of extended quinolone prophylaxis may
have played a protective role. Indeed some other
studies either administered prophylactic antibiotics
only when the neutrophil count was <0.5 · 109/L
(12, 15) and ﬂuconazole for 1 yr (31), but most did
not use any prophylaxis for bacterial (8, 11, 13) or
fungal infections (8, 11–13, 15). Fungal infections
were rather uncommon, in agreement with the
short duration of neutropenia considered as the
most important host defense mechanism against
fungal infections in this setting, and there was no
parasitic infection.
Bacteremia accounted for a higher proportion of
all infections in the CD34 compared with the PBSC
group. The vast majority of bacteremia occurred
during neutropenia that was of comparable length
in the two groups. In agreement with the literature
(32–34), most episodes of bacteremia were caused
by gram-positive coagulase-negative staphylococci
and streptococci. This could be due to the system-
atic use of central venous catheters, but the type
and duration of central intravascular device were
identical in the two populations. This could also
relate to mucositis and gastrointestinal toxicity, but
their incidence was similar in the two groups.
As CD34 selection may be associated with
qualitative or quantitative diﬀerences in immune
reconstitution as after allogeneic T-cell depletion
(5, 8–11), one could expect a surge in viral, and in
particular CMV, infections. However, the rate of
CMV infection was very low in both groups, and
there were only two cases of CMV disease, both in
the PBSC group. The actuarial rate of VZV
infection was quite similar in the two groups, with
very few cases of early zoster/varicella but with
VZV as the major agent responsible for infections
after day 100. Thus, overall, in our experience,
CD34 selection was not associated with an in-
creased risk of viral infection. This may come as a
surprise as several studies have shown an increased
incidence of viral, and in particular of CMV,
infections in recipients of CD34-selected grafts
(12, 15–17). In addition, the risk of Epstein–Barr
virus lymphoproliferative disease appears to be
enhanced (31, 35). However, other studies also did
not describe any augmentation of CMV and other
viral infections (8, 13). These diﬀerences among
studies can be partly due to diﬀerent patient
selection criteria or diﬀerent prophylaxis policies.
In particular, some studies were carried out without
any acyclovir prophylaxis (11, 13), but some used
acyclovir (8, 12, 15) up to 1 yr post-transplant (31).
Our policy of prolonged acyclovir prophylaxis may
have protected many patients from VZV infection
until more complete immune recovery. Diﬀerences
could also relate to low infection detection rates
when viral cultures and CMV PCR are not
routinely performed, as in our early patients.
Indeed, our result may be an underestimate because
of the lack of stringent monitoring for viral
infections. The speed of immune reconstitution
may also correlate inversely with the purity of the
CD34-selected product, hence with the degree of
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T-cell depletion, which was less severe in our series.
At least early monocyte and overall lymphocyte
recoveries were similar in our two groups. How-
ever, the retrospective nature of our analysis does
not allow us to evaluate immune recovery more
thoroughly, in particular for CD4 counts.
In conclusion, our results do not support the
notion that CD34-selection of the graft is associ-
ated with an increased rate of infection after
autologous PBSC transplantation. However, the
absence of a signiﬁcant diﬀerence between cases
and controls may relate to the relatively low
numbers of patients (although our study is one of
the largest, with 100 carefully matched patients)
and the relative heterogeneity of our population.
Alternatively, this could also be due to a more
vigorous infection prophylaxis in our patients
compared with those reported in other studies.
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